Danish medical tycoon buys buying worldwide rights to 25 herbal medical products

NewsGuard 100/100 Score

Danish medical tycoon, Erik Sprunk-Jansen, former CEO of pharmaceutical company Lundbeck, now implements an ambitious venture to create a global company for herbal medicine.

In one blow buying worldwide rights to 25 herbal medical products with extensive clinical and practical documentation Sprunk-Jansen A/S has obtained the position as a global player within herbal medicine, food supplies and creams.

Biochemist, Dr. Stephen Fulder, one of the world's leading experts within herbal medicine: "The 25 products all come from traditional Arabic medicine. The products work on various illnesses such as men's infertility, psoriasis, acne and increased cholesterol. These are illnesses that strike millions of people around the world."

10 years ago traditional Arabic medicine was about to be forgotten. But a group of Palestinian researchers in Israel formed a new company called Antaki to revive the tradition on a scientific basis. The 25 products are the first result of this work.

Chairman of Sprunk-Jansen A/S, Erik Sprunk-Jansen: "We have ensured the financial means to maintain the necessary speed in our development. We are going to work with own sales companies in the Nordic and Baltic markets and with licensees in more remote markets."

Prognoses for sales of natural products are promising with surging consumer demands for herbal medicine. Another reason is increasing costs for development of synthetic medicine.

Managing Director Rolf Sprunk-Jansen: "The brand of Sprunk-Jansen A/S is to be the consumers' guarantee for the effect and safety of the products. We add value to our brand working with partners like the international branding expert Wally Olins, the Dutch design company ping-pong Design and the Danish PR company Brinkmann + Partners. The butterfly will be the symbol of the products of the company".

Sprunk-Jansen A/S enters the Danish market at the end of the year and the Baltic countries in early 2005. Poland and the other Nordic countries will follow in 2005 and 2006. At the same time licensing agreements are to be made in the most promising markets, a.o. the US, Russia, Japan and Asia.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings